uMotif and ClinOne Unify eCOA/ePRO and eConsent to Improve the Participant Experience and Endpoint Data Quality in Global Clinical Trials

▤ Summary

“It is encouraging and refreshing to see so many sponsors and CROs adopt patient-first technologies like eCOA, ePRO (patient reported outcomes) and eConsent, but too often they are frustrated by disjointed solutions that place a high burden on users and limit effectiveness,” said Steve Rosenberg (LinkedIn), CEO of uMotif. “The work our customers do to save and improve lives is nothing short of inspiring, and as a technology ecosystem we share a responsibility to provide the patients, caregivers, and sites in their trials with the best experience possible,” said Andrea Valente (LinkedIn), ClinOne CEO. By engaging patients and healthcare professionals, uMotif is trusted by global pharmaceutical companies, biotech’s, CROs, and academic institutions to capture large volumes of eCOA/ePRO, symptom, and wearable device data. By offering choice to patients, caregivers, and site staff, our technology makes it easier to stay active, compliant, and comfortable in a trial – thereby expanding enrollment access, reducing drop-out rate, and shortening conduct timelines. ClinOne stands alone with the industry’s fastest implementation (average 2-4 weeks), cost-efficient scale, and seamless API integrations for complex therapeutic areas such as Oncology, CNS, and Rare Disease in over 60 languages.

▦ Linked Companies

ClinOne

$1M to $5M